ECX — Epigenomics AG Share News
0.000.00%
Last trade - 00:00- €0.61m
- -€2.62m
- €0.49m
Brief: Epigenomics Implements Measures To Reduce Costs During COVID-19 Pandemic
Brief: Epigenomics To Increase Share Capital By Way Of Private Placement
Brief: Epigenomics Postpones AGM, Comments On Coronavirus Impact
Brief: Epigenomics: Centers For Medicare & Medicaid Services Open NCD Review Process For Epi proColon
Brief: New Micro-Simulation Study In Cancer Medicine Finds Epi ProColon Provides Clinically Meaningful Reductions In Incidence, Mortality Of Colorectal Cancer
Brief: Epigenomics 9-month EBITDA Down At EUR -9.7 Mln
Brief: Epigenomics AG Says No Operational Reasons For Sharp Decline In Share Price
Brief: Epigenomics: Subscription Price Of Capital Increase At EUR 1.11 Per Share
Brief: Epigenomics To Increase Capital Through Rights Issue With Subscription Rights
Brief: Epigenomics H1 Net Loss Of EUR 7.4 Mln
Brief: Epigenomics: New Clinical Data On Epi ProColon Blood Test For Colorectal Cancer Screening
Brief: Epigenomics Q1 Net Loss Narrowed To EUR 3.0 Mln
Brief: Epigenomics AG Says CMS accepts Epigenomics' application for NCD review
Advisory: Alerts on Epigenomics FY revenue, forecast withdrawn
Brief: Epigenomics FY Net Loss Widens To EUR 12.7 Million
Brief: BioChain says Termination Of Contract By Epigenomics Is Not Legally Effective
Brief: Epigenomics AG Ends License Agreement With Biochain, Reports 2019 Outlook
Brief: Epigenomics Says Microsimulation Model Demonstrates Positive Results For Epi Procolon(R) Blood Test
Brief: Epigenomics Q3 Net Loss At EUR -3.0 Mln